» Articles » PMID: 32437790

Ginsenoside Rg1 Protects Against D-galactose Induced Fatty Liver Disease in a Mouse Model Via FOXO1 Transcriptional Factor

Overview
Journal Life Sci
Publisher Elsevier
Date 2020 May 22
PMID 32437790
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Rg1 is the most active component of traditional Chinese medicine ginseng, having anti-aging and anti-oxidative stress features in multiple organs. Cellular senescence of hepatocytes is involved in the progression of a wide spectrum of chronic liver diseases. In this study, we investigated the potential benefits and mechanism of action of Rg1 on aging-driven chronic liver diseases.

Materials And Methods: A total of 40 male C57BL/6 mice were randomly divided into four groups: control group; Rg1 group; Rg1+d-gal group; and d-gal group. Blood and liver tissue samples were collected for determination of liver function, biochemical and molecular markers, as well as histopathological investigation.

Key Findings: Rg1 played an anti-aging role in reversing d-galactose induced increase in senescence-associated SA-β-gal staining and p53, p21 protein in hepatocytes of mice and sustained mitochondria homeostasis. Meanwhile, Rg1 protected livers from d-galactose caused abnormal elevation of ALT and AST in serum, hepatic steatosis, reduction in hepatic glucose production, hydrogenic degeneration, inflammatory phenomena including senescence-associated secretory phenotype (SASP) IL-1β, IL-6, MCP-1 elevation and lymphocyte infiltration. Furthermore, Rg1 suppressed drastic elevation in FOXO1 phosphorylation resulting in maintaining FOXO1 protein level in the liver after d-galactose treatment, followed by FOXO1 targeted antioxidase SOD and CAT significant up-regulation concurrent with marked decrease in lipid peroxidation marker MDA.

Significance: Rg1 exerts pharmaceutic effects of maintaining FOXO1 activity in liver, which enhances anti-oxidation potential of Rg1 to ameliorate SASP and to inhibit inflammation, also promotes metabolic homeostasis, and thus protects livers from senescence induced fatty liver disease. The study provides a potential therapeutic strategy for alleviating chronic liver pathology.

Citing Articles

A Review of the Therapeutic Potential of Ginseng and Its Bioactive Components in Nonalcoholic Fatty Liver Disease.

Hao L, Li S, Li C, Zhang Z, Hu X, Yan H Drug Des Devel Ther. 2025; 19():83-96.

PMID: 39803604 PMC: 11725245. DOI: 10.2147/DDDT.S500719.


Dasatinib and Quercetin as Senolytic Drugs Improve Fat Deposition and Exhibit Antifibrotic Effects in the Medaka Metabolic Dysfunction-Associated Steatotic Liver Disease Model.

Yakubo S, Abe H, Li Y, Kudo M, Kimura A, Wakabayashi T Diseases. 2024; 12(12.

PMID: 39727647 PMC: 11727104. DOI: 10.3390/diseases12120317.


Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders.

Mor A, Tankiewicz-Kwedlo A, Ciwun M, Lewkowicz J, Pawlak D Cells. 2024; 13(15.

PMID: 39120289 PMC: 11311768. DOI: 10.3390/cells13151259.


Forkhead box O1 in metabolic dysfunction-associated fatty liver disease: molecular mechanisms and drug research.

Sha X, Zou X, Liu S, Guan C, Shi W, Gao J Front Nutr. 2024; 11:1426780.

PMID: 39021599 PMC: 11253077. DOI: 10.3389/fnut.2024.1426780.


Pharmacological potential of ginseng and ginsenosides in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Yi Y J Ginseng Res. 2024; 48(2):122-128.

PMID: 38465218 PMC: 10920004. DOI: 10.1016/j.jgr.2023.11.003.